Exosome Therapy vs Stem Cell Therapy for Hair Loss: What You Are Actually Comparing
“Stem cell therapy for hair loss” is one of the most searched terms in hair restoration, and one of the most misleading. It is not a single treatment. It is a marketing label applied to at least five different things, some of which are backed by clinical evidence, some of which are not, and one of which is illegal in UK aesthetic clinics.
Before we compare exosome therapy to stem cell therapy, we need to explain what stem cell therapy actually is, because the answer changes everything.
Book your consultation
"Stem cell therapy for hair loss" covers multiple different treatments.
Stem cell-derived exosomes are a cell-free alternative with growing clinical evidence, but are also unlicensed for injectable use in the UK
Exosome therapy works on follicle biology directly, not on hormone levels.
Exosome therapy at Hair Revive uses the E50 salmon-derived exosome, which is not stem cell therapy and is not stem cell-derived.
Stem Cell vs. Exosomes: The Short Answer
If someone is recommending "stem cell therapy" for your hair loss, the most important question you can ask is: what exactly is being used, where does it come from, and how is it administered? Let's first untangle the mess.
Live Stem Cell Therapy
If the answer is live cells injected into your scalp, that treatment does not have MHRA marketing authorisation for hair loss in the UK.
Stem Cell Derived Exosomes
If the answer is a stem cell-derived exosome product administered by injection, that sounds superficially similar to what Hair Revive offers but is actually a distinct category. These products are derived from human tissue, delivered by injection, and carry a different UK regulatory status.
E50 Exosomes
Exosome therapy at Hair Revive is not stem cell therapy.
It is a distinct treatment using E50, a salmon-derived exosome, delivered topically with microneedling and TargetCool.
It shares the broad category of extracellular vesicle therapy with stem cell-derived exosomes, but the two have different sources, different evidence, and different regulatory positions in the UK.
Plant Stem Cells
In the context of Hair Restoration, this is more or less always marketing fluff. A contradiction in itself.
Plant biology doesn't map to human hair follicles. Even if you had intact plant stem cells, they operate on entirely different biological pathways. A plant repairing its own damaged tissue is not analogous to a human follicle recovering from miniaturisation!
| E50 Exosome therapy (Hair Revive) | Stem cell-derived exosomes (MSC/ADSC) | Live stem cell therapy (SVF/ADSC) | |
|---|---|---|---|
| What it is | Extracellular vesicles derived from salmon cells | Extracellular vesicles derived from human mesenchymal or adipose stem cells | Living adipose-derived stem cells or stromal vascular fraction, injected into the scalp |
| Contains living cells? | No (acellular) | No (acellular) | Yes |
| Source | Non-human (salmon) | Human donor stem cells (allogeneic) or patient's own tissue (autologous) | Patient's own fat tissue (autologous) or donor source |
| How administered | Topically, with microneedling and TargetCool at Hair Revive | Typically by scalp injection in clinical practice | Scalp injection, after liposuction extraction and processing |
| UK regulatory status | Non-human (Salmon), topical application: permissible as cosmetic ingredient | Unlicensed for injectable use; no MHRA marketing authorisation | Unlicensed ATMP; no MHRA marketing authorisation for hair loss |
| Clinical evidence | 2 RCTs, 9 additional studies, 2025 systematic review (11 studies, 298 patients) | Observational data from manufacturer; not included in any peer-reviewed systematic review | 2024 systematic review: 12 RCTs, 514 patients; 17–102 hairs/cm² density increase |
| NICE / NHS | Not NICE-recommended or NHS-provided | Not NICE-recommended or NHS-provided | Not NICE-recommended or NHS-provided |
| Human disease transmission risk | None (non-human source) | Possible with allogeneic human-derived products | Low (autologous); higher with allogeneic sources |
What "Stem Cell Therapy" Actually Means for Hair Loss
The term covers a spectrum. Here are the main categories and what each one actually is.
Live Stem Cells
Live cell therapy: SVF and ADSC injection
At the most intensive end is therapy involving actual living cells. Stromal vascular fraction (SVF) is extracted from the patient's own liposuctioned fat, processed to isolate a mixture including mesenchymal stem cells (MSCs), and then injected into the scalp.
Adipose-derived stem cell (ADSC) therapy involves a similar process, sometimes with cells cultured and expanded before injection.
A 2024 systematic review in Plastic and Reconstructive Surgery: Global Open covering twelve RCTs and 514 patients found hair density increases ranging from 17 to 102 hairs per cm² in studies using cellular and acellular therapies combined, with one SVF and PRP study showing a 51.64% increase in hair density.
The regulatory position in the UK is clear: these treatments require MHRA marketing authorisation as Advanced Therapy Medicinal Products (ATMPs). No SVF or ADSC preparation holds that authorisation for hair loss. Clinics offering live stem cell injections for hair restoration in the UK are operating outside the licensed framework.
Live Stem Cells
Cell-free growth factors from stem cells
Conditioned media (also called secretome) is the liquid in which stem cells have been cultured. The cells are removed before use; what remains is a collection of growth factors, cytokines and nano-sized vesicles shed by the stem cells during culture. No living cells are injected.
The best-studied commercial product in this category is AAPE (Advanced Adipose-derived stem cell Protein Extract), developed in South Korea. A 2023 RCT published in Stem Cell Research and Therapy of 37 men comparing ADSC conditioned media plus topical minoxidil against saline plus minoxidil found statistically significant improvements in hair count, density and thickness. A 2023 systematic review in the Journal of Plastic, Reconstructive and Aesthetic Surgery (00608-3/abstract) across eight trials and 221 participants found conditioned media produced a mean increase in hair density of 14.93 hairs per cm².
Conditioned media remains an unlicensed treatment for injectable use in the UK.
Stem Cell Exosomes
Stem cell-derived exosomes
Stem cell-derived exosomes are the nano-sized vesicles produced by MSCs or ADSCs during culture. They carry the growth factors, microRNA and signalling proteins that mediate much of the biological effect attributed to stem cells, without any living cells being present.
This is the fastest-growing category in regenerative hair treatment. A 2025 systematic review covering eleven clinical studies and 298 patients found consistent improvements across MSC-exosome sources: ADSC-exosomes (the best evidenced, with two RCTs) produced density increases of up to 35 hairs per cm² and a mean thickness improvement of 13 micrometres, with patient satisfaction averaging 8.5 out of 10 in the largest RCT.
Like other injectable exosome products, stem cell-derived exosomes do not hold MHRA marketing authorisation for hair loss in the UK. Save Face, the UK's leading aesthetic safety accreditor, has issued a formal patient safety warning stating that injectable exosome therapies cannot lawfully be used in UK aesthetic procedures.
What is not stem cell therapy
Two categories are marketed as stem cell therapy but contain no stem cells:
PRP rebranded as stem cell therapy. Platelet-rich plasma contains platelets and growth factors from the patient's blood. It does not contain stem cells. Some clinics describe PRP as "stem cell activation" or frame it under stem cell branding. This is a mislabelling of an otherwise legitimate treatment.
Plant stem cell serums. Products described as containing apple, raspberry or argan stem cell extracts are cosmetic products. The plant cells are destroyed during extraction; what remains is a mixture of plant peptides and antioxidants. There are no living cells in these products, and no human or animal biology. A review of stem cell-related commercial fraud identified this as a deliberate consumer confusion strategy exploiting the premium pricing the label commands.
Likewise, E50 Exosome Treatment is not Stem Cell Therapy, though it is not marketed as such.
What Is Exosome Therapy for Hair Loss?
Exosomes are tiny signalling parcels released by cells, packed with growth factors, microRNA and other molecules.
Exosome therapy for hair loss delivers a concentrated preparation of these parcels to the scalp, with the aim of prompting struggling follicles to function better.
At Hair Revive we use the E50 Exosome preparation, which is salmon-derived, and we deliver it topically with microneedling and TargetCool, not by injection.
Why the Field Has Moved Towards Cell-Free Approaches
The shift from live stem cell injections to cell-free therapies is not a single step.
It is a gradual progression with three distinct stages, each representing a different set of trade-offs between efficacy, safety, practicality and UK regulatory standing.
01
Live stem cell therapy (SVF and ADSC injections)
The original regenerative approach involves actual living cells: SVF extracted by liposuction, or ADSCs isolated and sometimes expanded in culture before injection into the scalp.
The biological rationale is sound and evidence of effect exists, but the practical and regulatory barriers are significant.
The procedure requires liposuction, takes four hours or more, and the products are unlicensed ATMPs in the UK. Live stem cells from allogeneic (donor) sources also carry risks that cell-free products do not: immune rejection, uncontrolled cell migration and, with incompletely differentiated cells, the theoretical risk of abnormal tissue growth.
02
Stem cell-derived exosomes
Research into why stem cell injections work revealed that much of the benefit was paracrine in nature. The injected cells were not integrating into new tissue; they were secreting growth factors, cytokines and extracellular vesicles that triggered the body's own regeneration. If the cells' main contribution was what they released, why inject the cells at all?
Conditioned media and stem cell-derived exosomes are the direct result of that question. By culturing MSCs or ADSCs and collecting what they secrete, the same biological signals are delivered without the cells themselves.
This removes the risks of immune rejection and uncontrolled migration, simplifies storage and preparation, and produces a more consistent, measurable product. MSC and ADSC-derived exosomes now have two RCTs and a 2025 systematic review of eleven studies behind them. They are still unlicensed for injectable use in the UK, but they represent a meaningful step beyond live cell therapy in both safety profile and evidence quality.
03
Non-human topical exosomes
The E50 used at Hair Revive is not part of the stem cell-derived lineage. It is derived from salmon cells, not from human or mammalian stem cells.
Its position in this landscape is not "more advanced than MSC-exosomes" or "less advanced." It is a different category: a non-human, topically applied extracellular vesicle product.
The regulatory implication of that distinction is significant. Because it is non-human and is not injected, it sits outside both MHRA's ATMP framework and Save Face's patient safety warning on injectable exosomes.
It does not carry human disease transmission risk. It does not require the liposuction harvest that live cell therapy demands. What it does not have, and this article is explicit about this, is the same depth of peer-reviewed clinical evidence that MSC-exosome products have accumulated.
What the Research Shows
This is where the two treatments differ most clearly.
Live Stem Cells
Live stem cell therapy (SVF and ADSC injections)
Evidence for SVF and ADSC injections comes primarily from the 2024 systematic review in Plastic and Reconstructive Surgery: Global Open, which covered twelve RCTs and 514 patients across cellular and acellular therapies. Studies using SVF with adjuncts showed density increases ranging from 17 to 102 hairs per cm². A 2022 systematic review covering nine studies and 236 patients found consistent positive findings for SVF specifically.
The clinical evidence is meaningful, but it cannot be separated from the regulatory picture. These studies were conducted under controlled research conditions or in jurisdictions with different regulatory frameworks. In UK aesthetic practice, SVF and ADSC injections for hair loss are unlicensed commercial procedures. Evidence of biological effect does not make them lawful.
Stem Cell Exosomes
The Strongest Emerging Evidence
The most developed peer-reviewed evidence in this field belongs to MSC and ADSC-exosome products. The 2025 systematic review covering eleven clinical studies and 298 patients found positive results in all included studies. ADSC-exosomes had the best individual evidence: density increases of up to 35 hairs per cm², mean thickness improvements of 13 micrometres, and patient satisfaction averaging 8.5 out of 10 in the largest RCT. Two of the eleven studies were RCTs.
Conditioned media findings from the 2023 ADSC-CM RCT and the 2023 JPRAS meta-analysis00608-3/abstract) (eight trials, 221 participants; +14.93 hairs per cm²) reflect the same paracrine biology and show comparable positive findings.
Limitations apply across all of these studies: small sample sizes, short follow-up periods, and significant heterogeneity in products, dosing and administration methods. But within the emerging regenerative category, stem cell-derived exosomes have the most developed evidence base of the three approaches discussed here.
E50 Exosomes
An Alternative With a Bright Future
The E50 does not appear in any peer-reviewed systematic review of exosome or stem cell therapy for hair loss. The 2025 systematic review included no non-mammalian exosome sources.
Clinical data supporting the E50 specifically comes from observational studies and practitioner-reported outcomes provided by the manufacturer, not from independent peer-reviewed trials.
This is the honest picture, and Hair Revive states it directly.
The biological mechanism of the E50 is plausible and consistent with the broader extracellular vesicle evidence. The safety profile is favourable: no serious adverse events have been reported in the published literature for topical salmon-derived exosome use. But the E50's specific peer-reviewed clinical evidence is limited and should not be described as equivalent to that of MSC-exosome products.
That said, the future is bright, and at Hair Revive, we have seen the results with our own eyes. The treatment has helped hundreds of patients so far.
E50 Exosomes
Our Experience at Hair Revive
We began offering E50 Treatment to our clinic in early 2025.
The pattern we see in practice is broadly consistent with what the wider exosome literature reports: where patients have early-to-mid-stage pattern hair loss and follicles are still present, many go on to see improvements in density and hair condition over the course of treatment.
In cases where follicles are no longer active or the hair loss is advanced, the response is limited, which is why we assess every patient before agreeing a course.
This is clinical observation from practice, not a published audit, and we describe it that way. It informs how we approach patient selection and contributes to our confidence in the protocol. It is not a substitute for peer-reviewed evidence, and we are not presenting it as such.
Clinical Observations at The Hair Revive Clinic
We've proudly offered E50-H Treatment for over a year in our Clinic and tracked our own visitors progress over time.
Visit our Results Page to some of the transformations we've achieved:
VISITOR RESULTS →
The UK Regulatory Picture
A 2021 Abertay University study found that 79% of examined UK stem cell clinics displayed ethically problematic marketing material, most failed to disclose any risks, and none linked to completed clinical trials for their specific treatments. The consumer due diligence bar in this category is high.
Live Stem Cells
Unlicensed ATMP
SVF extractions and ADSC injections are Advanced Therapy Medicinal Products under UK law.
No preparation of this kind holds MHRA marketing authorisation for hair loss.
Clinics offering live stem cell injections for hair restoration as a commercial procedure are operating outside the licensed framework, regardless of how the treatment is branded. Patients receiving such treatment are receiving an unlicensed product and should understand that clearly before proceeding.
Stem Cell Exosomes
Unlicensed for injectable use
Human-derived exosome products, including MSC and ADSC-exosomes, do not hold MHRA marketing authorisation for hair loss in the UK. Save Face has issued a formal patient safety warning stating that injectable exosome therapies cannot lawfully be used in UK aesthetic procedures. This applies regardless of the sophistication of the product or the clinical credentials of the clinic offering it.
This does not mean no clinics administer these products commercially. It means patients should understand they would be receiving an unlicensed treatment, and should ask specific questions about how the clinic frames that before consenting.
E50 Exosomes
A different regulatory category
The E50 sits in a different position because of two specific factors: it is derived from non-human cells (salmon) and it is applied topically, not by injection.
Save Face's own guidance acknowledges that animal-sourced exosomes used topically are legal alternatives to the prohibited categories. The E50, delivered post-microneedling at Hair Revive and not administered by injection, falls within this permissible category.
This does not remove all regulatory considerations. Any clinic using a topical exosome product should operate under CQC registration and GMC-registered medical oversight. Hair Revive holds both.
The Bottom Line: Which Treatment is Right for You?
A consultation will take account of your current medications, your history with any previous treatments, and your pattern of loss before advising on next steps.
Live Stem Cell Therapy
You are exploring the most intensive regenerative option and have been assessed by a specialist in a jurisdiction where the procedure is lawfully offered
You want an autologous (your own tissue) source with no human donor disease transmission risk
You have been clearly informed of the unlicensed status in the UK and are proceeding under appropriate clinical oversight and informed consent
Note: Hair Revive does not offer live stem cell therapy. If you are seriously considering it, independent medical advice from a specialist experienced in UK ATMP regulation is essential before proceeding
Stem Cell Derived Exosomes
You are specifically seeking a human-biology-derived exosome preparation with the most developed peer-reviewed evidence base in the exosome category
You are accessing it via a clinic that administers it under appropriate clinical supervision and is transparent about the unlicensed status of any injectable product
Note: Hair Revive does not offer injectable MSC or ADSC-exosome products
E50 Exosome Therapy
You want a topical, non-injectable protocol that sits clearly within UK legal parameters for aesthetic use
You want a non-human-derived product with no human disease transmission risk
You are looking for a CQC-registered, GMC-led clinic with a defined, consistent protocol
You prefer a clinic that is transparent about the evidence base, including its limitations
None of these are suitable if:
Follicles in the target area are completely dormant (surgical assessment is more appropriate)
You have a scarring alopecia or an active scalp infection
You are pregnant or breastfeeding
You have a medical condition that makes either treatment clinically unsuitable
Is Exosome Hair Restoration Therapy Right For You?
In a world of endless serums, tinctures and procedures it's easy to feel like you're going round in circles.
Exosome Therapy isn't for everybody, and we're upfront about that.
Our 2 Minute Suitability Quiz helps you get a clear picture on whether to proceed with this Treatment or not.
Frequently Asked Questions About Stem Cell Hair Therapy
It depends on which treatment is being described. Live stem cell injections (SVF, ADSC) require MHRA marketing authorisation as Advanced Therapy Medicinal Products; no preparation holds that authorisation for hair loss in the UK. Stem cell-derived exosome products are in a parallel position: injectable human-derived exosome products are also unlicensed, and Save Face has issued a specific patient safety warning covering them. Topical non-human exosome products, such as the salmon-derived E50 at Hair Revive, sit in a different regulatory category and are permissible as topical cosmetic ingredients. If a clinic cannot tell you exactly which of these categories its product falls into and whether it is licensed, that is a significant red flag.
The terms cover three distinct things, which is the source of most consumer confusion. Live stem cell therapy (SVF or ADSC injection) involves actual living cells extracted from the patient's own fat tissue and injected into the scalp. Stem cell-derived exosome therapy is a cell-free step forward from that: it delivers the signalling vesicles that stem cells produce during culture, without the cells themselves, and has the strongest peer-reviewed evidence in this category. The E50 used at Hair Revive is a third category entirely: it is salmon-derived, not stem cell-derived, and is applied topically rather than by injection. Each has a different evidence base, a different regulatory position in the UK, and a different practical profile for patients.
On peer-reviewed evidence, MSC and ADSC-exosomes currently have a stronger clinical record, including RCT data showing density improvements of up to 35 hairs per cm². Salmon-derived exosome products like the E50 do not appear in peer-reviewed systematic reviews. The honest answer is that MSC-exosome products have more published evidence; the E50 has a more favourable UK regulatory position (non-human, topical, no human disease transmission risk) but less clinical trial data.
Not commercially. Injecting stem cells (SVF, ADSC) or human-derived exosomes into patients for hair loss without MHRA marketing authorisation as an ATMP is unlicensed in the UK. This does not mean no clinics do it, but patients should understand they would be receiving an unlicensed treatment.
Ask what the product is, where it comes from, and whether it contains living cells. Many products marketed as stem cell therapy contain no stem cells: conditioned media contains no cells at all, exosome preparations contain no cells, PRP contains no stem cells, and plant stem cell serums contain no human or animal biology whatsoever. A clinic that responds to this question with vague marketing language rather than a specific answer is not giving you the information you need to make a safe decision.
No. We specialise in exosome therapy using the E50 salmon-derived preparation, delivered topically with microneedling and TargetCool. The E50 is not stem cell-derived and is not stem cell therapy. If after a consultation we believe another treatment would be more appropriate for your case, we will say so.
No direct comparative trial exists. The two have not been tested head to head. The biological mechanisms are conceptually similar, but the specific evidence bases are separate and unequal: MSC-exosome products have more published peer-reviewed evidence. Hair Revive operates transparently about this, including in this article.
The Best Time To Start Your Hair Restoration Journey? Yesterday.
The second best time? TODAY!
If you're ready to start making meaningful progress towards fuller, thicker hair, then get in touch today.
We are honest and transparent about your potential, and will always set clear expectations, even before you visit us.
So what have you got to lose? Get in touch Today.
Book Online
Call
Text
Visit
Hair Revive at Dr Aesthetica
Unit 1, 1431–1433 Bristol Road South
Birmingham, West Midlands B31 2SU